University of Wisconsin, Madison
The goal of this clinical trial is to see if a drug called 18F-DCFPyL can help find prostate cancer or prostate cancer that has spread to other parts of the body. The main question it aims to answer is: * Can 18F-DCFPyL predict response to therapy; and, * Does 18F-DCFPyL improve detection of early signs of cancer. Participants will undergo PET/MRI scans.
Evaluate PSMA PET/MRI imaging as a method for determining: 1. Treatment response in primary prostate cancer after neoadjuvant systemic therapy in men with high-risk prostate cancer; and, 2. Detection of clinically significant cancer in men with very low to intermediate risk primary prostate cancer.
Inclusion Criteria - Sub-study 1: * Participant must be ≥ 18 years of age * Participant must have an ECOG performance status ≤ 1. * High risk disease (NCCN criteria Gleason 8-10 or PSA\>20) or oligometastatic * Histologic confirmation of prostate adenocarcinoma of the prostate gland, with or without evidence of metastases (oligometastatic \<10 sites) on imaging by conventional imaging (MRI, CT, or 99mTc bone scan) or PSMA PET/CT * Newly diagnosed disease with no prior treatment (surgery, radiation or systemic treatment, hormone therapy or chemotherapy) to the primary disease * Participants…
Participants will complete 75 minutes of scans.
Participants will complete 75 minutes of scans.
18F-DCFPyL will be injected through an IV in the arm.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.